Exosome Diagnostics MedOncAlyzer 170

Aug 09, 2017

Exosome Diagnostics launched the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that interrogates exosomal RNA and circulating tumor DNA in one assay. MedOncalyzer 170 is a targeted panel for tumor profiling that identifies clinically actionable and functionally important mutations across multiple cancer types, using as little as 0.5 ml of patient blood or plasma.

Breaking News

People in the News at Integrated DNA Technologies, AdvaMedDx, Waters, Pacific Edge
New Products Posted to GenomeWeb: Illumina, Fujirebio, Tianlong, Telesis Bio, BioEcho Life Sciences
Pediatric Cancer Cell Atlas Uncovers Clues About Cancer Drivers, Treatment Targets
TD Cowen Upgrades Shares of Pacific Biosciences to Outperform
In Brief This Week: Interpace Biosciences, ProPhase Labs, OpGen, Centogene, Seegene, Freenome, More

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.